Cited 12 times in
Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 홍성준 | - |
dc.date.accessioned | 2015-12-28T11:02:31Z | - |
dc.date.available | 2015-12-28T11:02:31Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0919-8172 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/138566 | - |
dc.description.abstract | OBJECTIVES: To evaluate the safety and efficacy of abiraterone acetate and prednisolone in Korean and Taiwanese patients with metastatic castration-resistant prostate cancer not responding to docetaxel-based chemotherapy. METHODS: In this single-arm study, 82 metastatic castration-resistant prostate cancer patients who failed docetaxel-based chemotherapy were treated with abiraterone (1000 mg, once daily) and prednisolone (5 mg, twice daily). Patients achieving a prostate-specific antigen decline ≥ 50% were considered as responding. RESULTS: A total of 35 patients (43%) achieved prostate-specific antigen response (95% confidence interval 32-54). The median time to prostate-specific antigen progression was 4.7 months (95% confidence interval 3.7-8.3); the median overall survival was 11.8 months. Two (4%) of 50 patients with measurable disease achieved partial response. The median testosterone concentration was in the castration range (1.21 nmol/L) throughout the treatment period. Median dehydroepiandrosterone sulfate decreased from 0.725 μmol/L (baseline) to 0.080 μmol/L (cycle 4). The most common adverse event was bone pain (20%); grade 3/4 adverse event of special interest were hypokalemia (7%), fluid retention and liver function abnormalities (5% each), hypertension (2%), and cardiac disorders (1%). CONCLUSIONS: A combination of abiraterone acetate and prednisolone appears to be a favorable second-line treatment in Taiwanese and Korean patients with advanced metastatic castration-resistant prostate cancer after failed docetaxel-based chemotherapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1239~1244 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF UROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Androgens/metabolism* | - |
dc.subject.MESH | Androstenes/administration & dosage* | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage | - |
dc.subject.MESH | Disease Progression | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Glucocorticoids/administration & dosage | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Incidence | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Orchiectomy* | - |
dc.subject.MESH | Prednisolone/administration & dosage* | - |
dc.subject.MESH | Prostatic Neoplasms, Castration-Resistant/drug therapy* | - |
dc.subject.MESH | Prostatic Neoplasms, Castration-Resistant/epidemiology | - |
dc.subject.MESH | Prostatic Neoplasms, Castration-Resistant/secondary | - |
dc.subject.MESH | Republic of Korea/epidemiology | - |
dc.subject.MESH | Survival Rate/trends | - |
dc.subject.MESH | Taiwan/epidemiology | - |
dc.subject.MESH | Taxoids/therapeutic use* | - |
dc.subject.MESH | Treatment Failure | - |
dc.title | Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Urology (비뇨기과학) | - |
dc.contributor.googleauthor | Cheol Kwak | - |
dc.contributor.googleauthor | Tony Tong Lin Wu | - |
dc.contributor.googleauthor | Hyun Moo Lee | - |
dc.contributor.googleauthor | Hsi Chin Wu | - |
dc.contributor.googleauthor | Sung Joon Hong | - |
dc.contributor.googleauthor | Yen Chuan Ou | - |
dc.contributor.googleauthor | Seok Soo Byun | - |
dc.contributor.googleauthor | Hyou Young Rhim | - |
dc.contributor.googleauthor | Thian Kheoh | - |
dc.contributor.googleauthor | Ying Wan | - |
dc.contributor.googleauthor | Howard Yeh | - |
dc.contributor.googleauthor | Margaret K Yu | - |
dc.contributor.googleauthor | Choung Soo Kim | - |
dc.identifier.doi | 10.1111/iju.12589 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A04402 | - |
dc.relation.journalcode | J01169 | - |
dc.identifier.eissn | 1442-2042 | - |
dc.identifier.pmid | 25099185 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/iju.12589/abstract | - |
dc.subject.keyword | abiraterone acetate | - |
dc.subject.keyword | docetaxel | - |
dc.subject.keyword | metastatic castration-resistant prostate cancer | - |
dc.subject.keyword | prednisolone | - |
dc.subject.keyword | prostate-specific antigen | - |
dc.contributor.alternativeName | Hong, Sung Joon | - |
dc.contributor.affiliatedAuthor | Hong, Sung Joon | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 21 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1239 | - |
dc.citation.endPage | 1244 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF UROLOGY, Vol.21(12) : 1239-1244, 2014 | - |
dc.identifier.rimsid | 38407 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.